ANGANY is an emerging, private pharmaceutical company, based in Quebec City, Canada. ANGANY has tackled the specific challenges of allergy to invent first-in class pharmaceuticals. ANGANY has developed an exclusive vaccine platform based on synthetic biology: the eBioparticle ™ self-adjuvant vector. ANGANY also produces high quality, high purity allergens for diagnostic purposes. Finally, ANGANY has developed a flexible, fast and highly scalable 3rd generation plant production platform. ANGANY's vaccine approach opens the door to applications in cancer, infectious, autoimmune diseases and others. ANGANY is a Franco-Canadian collaboration led by Louis-Philippe Vézina, a renowned pharmaceutical entrepreneur.